Personalis Inc (PSNL) Stock Price, Quote & News

Company Profile

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor an...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 650 752 1300

Fax: 650 752 1301

Website: www.personalis.com

Address:

6600 Dumbarton Circle, Fremont, United States

JFDI May. 13 at 3:24 PM

Maybe if you took it a lil more $PSNL You wouldn’t $BE …

0 · Reply

BioTechNoir May. 13 at 3:08 PM

$PSNL new goal 30k shares

0 · Reply

arribaStocktrading May. 13 at 3:03 PM

$PSNL It's not like people came out of the woodwork to sell today because the Market offered them a breadcrumb. And even the high of the day is a breadcrumb compared to what the news is. This is the market makers shorting out the morning buyers and then manipulating the price lower so your loss is their gain. Did I expect this to happen? Is rain wet? I hate those scummy bastards so much but I don't let them beat me. Hold on because it gets better - in spite of the blatant fuckery.

0 · Reply

RockyMontana May. 13 at 2:57 PM

$PSNL always, when im too bullish. I need to straight myself out.

0 · Reply

Wax_Bean_futures May. 13 at 2:41 PM

$PSNL just tell me we don't turn red. Which wouldn't surprise me lately but...... Lets freaking go

0 · Reply

Farorm May. 13 at 2:36 PM

$PSNL looks like I’m a bag holder

0 · Reply

BioTechNoir May. 13 at 2:32 PM

$PSNL added

0 · Reply

BeeDecay May. 13 at 2:00 PM

$PSNL the large blocks are at the buy side.

0 · Reply

BeeDecay May. 13 at 1:58 PM

$PSNL grabbed some extra, 6.55

0 · Reply

arribaStocktrading May. 13 at 1:51 PM

$PSNL I watched $AAOI go up $50 between Monday and the first 10 minutes of Tuesday for NO FUCKING REASON. This market is an insult to the intelligence of anyone with a brain that works.

2 · Reply

Personalis announces that CMS program expanded coverage for NeXT

May 13, 2026, 6:00 AM EDT - 5 hours ago

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

May 12, 2026, 12:00 PM EDT - 23 hours ago

Personalis Transcript: AGM 2026

2026-05-12T15:08:02.000Z - 1 day ago

Personalis price target lowered to $9 from $10 at Morgan Stanley

2026-05-11T12:19:55.000Z - 2 days ago

Personalis price target lowered to $11 from $13 at BTIG

2026-05-07T22:45:48.000Z - 5 days ago

Personalis files automatic mixed securities shelf

2026-05-07T21:26:54.000Z - 5 days ago

Personalis reports Q1 EPS (29c), consensus (27c)

2026-05-07T21:25:28.000Z - 5 days ago

Personalis affirms FY26 revenue view of $78M-$80M, consensus $78.8M

May 7, 2026, 5:00 PM EDT - 5 days ago

Personalis Earnings Call Transcript: Q1 2026

May 7, 2026, 4:01 PM EDT - 5 days ago

Personalis Reports First Quarter Results and Recent Highlights

2026-05-05T15:25:38.000Z - 8 days ago

Personalis management to meet virtually with Lake Street

Apr 23, 2026, 4:01 PM EDT - 19 days ago

Personalis to Announce First Quarter 2026 Financial Results

Apr 21, 2026, 6:00 AM EDT - 22 days ago

Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026

Apr 13, 2026, 6:00 AM EDT - 4 weeks ago

Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026

Apr 1, 2026, 4:01 PM EDT - 5 weeks ago

Personalis to Participate in the 25th Annual Needham Virtual Conference

2026-03-17T20:15:19.000Z - 2 months ago

Personalis names Richard Chen president

Mar 17, 2026, 4:00 PM EDT - 2 months ago

Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

2026-03-12T10:16:13.000Z - 2 months ago

Personalis’ NeXT Personal test shows predictive efficacy in breast cancer

Mar 12, 2026, 6:00 AM EDT - 2 months ago

Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®

2026-03-05T14:28:06.000Z - 2 months ago

Personalis price target lowered to $10 from $11 at Morgan Stanley

Feb 26, 2026, 5:00 PM EST - 2 months ago

Personalis Earnings Call Transcript: Q4 2025

2026-02-26T21:47:54.000Z - 2 months ago

Personalis sees FY26 revenue $78M-$80M, consensus $81.7M

2026-02-26T21:18:27.000Z - 2 months ago

Personalis reports Q4 EPS (26c), consensus (28c)

Feb 26, 2026, 4:01 PM EST - 2 months ago

Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

Feb 17, 2026, 4:01 PM EST - 3 months ago

Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

Feb 12, 2026, 4:01 PM EST - 3 months ago

Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

2026-02-10T11:21:43.000Z - 3 months ago

Personalis’ MRD test receives Medicare coverage in lung cancer surveillance

Feb 10, 2026, 6:00 AM EST - 3 months ago

Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance

2026-02-02T11:10:08.000Z - 3 months ago

Personalis announces publication of new study on NeXT Personal

Feb 2, 2026, 6:00 AM EST - 3 months ago

Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors

Jan 28, 2026, 4:01 PM EST - 3 months ago

Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

2026-01-26T14:41:40.000Z - 3 months ago

Personalis price target raised to $13 from $12 at Guggenheim

Jan 12, 2026, 4:00 PM EST - 4 months ago

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

2026-01-08T13:26:40.000Z - 4 months ago

Personalis sees FY25 revenue $69M-$70M, consensus $69.96M

2026-01-08T13:20:13.000Z - 4 months ago

Personalis narrows Q4 revenue view to $17M-$18M from $15.7M-$20.7M

Jan 8, 2026, 8:00 AM EST - 4 months ago

Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

Dec 17, 2025, 6:00 AM EST - 5 months ago

Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

Dec 11, 2025, 9:00 AM EST - 5 months ago

New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

Nov 18, 2025, 4:01 PM EST - 6 months ago

Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 6 months ago

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

Nov 4, 2025, 5:00 PM EST - 6 months ago

Personalis Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:01 PM EST - 6 months ago

Personalis Reports Third Quarter 2025 Financial Results

Oct 21, 2025, 4:01 PM EDT - 7 months ago

Personalis to Announce Third Quarter 2025 Financial Results

Oct 16, 2025, 9:00 AM EDT - 7 months ago

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

Sep 15, 2025, 5:35 PM EDT - 8 months ago

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 10, 2025, 4:05 PM EDT - 8 months ago

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Sep 3, 2025, 4:05 PM EDT - 8 months ago

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Aug 27, 2025, 4:01 PM EDT - 9 months ago

Personalis to Participate in Upcoming Investor Conferences

Aug 5, 2025, 5:00 PM EDT - 10 months ago

Personalis Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:01 PM EDT - 10 months ago

Personalis Reports Second Quarter 2025 Financial Results

Jul 22, 2025, 4:01 PM EDT - 10 months ago

Personalis to Announce Second Quarter 2025 Financial Results

Jul 9, 2025, 4:00 PM EDT - 10 months ago

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

TEM

Jun 3, 2025, 4:00 PM EDT - 1 year ago

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

Jun 2, 2025, 4:00 PM EDT - 1 year ago

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

May 22, 2025, 6:00 AM EDT - 1 year ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

May 14, 2025, 4:01 PM EDT - 1 year ago

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 6, 2025, 5:00 PM EDT - 1 year ago

Personalis Earnings Call Transcript: Q1 2025

May 6, 2025, 4:01 PM EDT - 1 year ago

Personalis Reports First Quarter 2025 Financial Results

Apr 28, 2025, 5:00 PM EDT - 1 year ago

Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

Apr 22, 2025, 4:01 PM EDT - 1 year ago

Personalis to Announce First Quarter 2025 Financial Results

Apr 22, 2025, 6:00 AM EDT - 1 year ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Mar 26, 2025, 4:01 PM EDT - 1 year ago

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

Mar 3, 2025, 6:00 AM EST - 1 year ago

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Feb 27, 2025, 5:00 PM EST - 1 year ago

Personalis Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:01 PM EST - 1 year ago

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 18, 2025, 4:01 PM EST - 1 year ago

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Feb 13, 2025, 4:01 PM EST - 1 year ago

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Jan 28, 2025, 4:01 PM EST - 1 year ago

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 13, 2025, 5:00 AM EST - 1 year ago

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Jan 7, 2025, 4:01 PM EST - 1 year ago

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

Dec 19, 2024, 9:00 AM EST - 1 year ago

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Dec 16, 2024, 8:00 AM EST - 1 year ago

Personalis and Tempus Expand Collaboration to Biopharma

TEM

Nov 20, 2024, 4:01 PM EST - 1 year ago

Personalis to Participate at Upcoming Investor Conferences

Nov 6, 2024, 5:00 PM EST - 1 year ago

Personalis Earnings Call Transcript: Q3 2024

Nov 6, 2024, 4:01 PM EST - 1 year ago

Personalis Reports Third Quarter 2024 Financial Results

JFDI May. 13 at 3:24 PM

Maybe if you took it a lil more $PSNL You wouldn’t $BE …

0 · Reply

BioTechNoir May. 13 at 3:08 PM

$PSNL new goal 30k shares

0 · Reply

arribaStocktrading May. 13 at 3:03 PM

0 · Reply

RockyMontana May. 13 at 2:57 PM

$PSNL always, when im too bullish. I need to straight myself out.

0 · Reply

Wax_Bean_futures May. 13 at 2:41 PM

$PSNL just tell me we don't turn red. Which wouldn't surprise me lately but...... Lets freaking go

0 · Reply

Farorm May. 13 at 2:36 PM

$PSNL looks like I’m a bag holder

0 · Reply

BioTechNoir May. 13 at 2:32 PM

$PSNL added

0 · Reply

BeeDecay May. 13 at 2:00 PM

$PSNL the large blocks are at the buy side.

0 · Reply

BeeDecay May. 13 at 1:58 PM

$PSNL grabbed some extra, 6.55

0 · Reply

arribaStocktrading May. 13 at 1:51 PM

$PSNL I watched $AAOI go up $50 between Monday and the first 10 minutes of Tuesday for NO FUCKING REASON. This market is an insult to the intelligence of anyone with a brain that works.

2 · Reply

BeeDecay May. 13 at 1:50 PM

$PSNL A steal under 7.

2 · Reply

RockyMontana May. 13 at 1:42 PM

$PSNL those know knows qualmaggie, this is an episodic pivot, an entry for traders to participate in this rally. More to come

0 · Reply

LucienW May. 13 at 1:41 PM

$PSNL Good news today. Final piece of risk removed. Here is cherry on top - according to latest filings, Vanguard just bought a big chunk of shares. It’s nice we are continuing to gain the attention of the big boys.

0 · Reply

E444 May. 13 at 1:37 PM

$PSNL weeee

0 · Reply

kherman255 May. 13 at 1:18 PM

$PSNL Hope not, but will probably see a rug pull at open.

0 · Reply

Farorm May. 13 at 1:15 PM

$PSNL back in after selling out 🚀

0 · Reply

arribaStocktrading May. 13 at 12:43 PM

$PSNL "Their smiles returning to their faces" https://youtu.be/DF5emO1X0HA?si=uDzF4Zkm-jb8KWxj

0 · Reply

BioTechNoir May. 13 at 12:38 PM

$PSNL lets see some analyst upgrades!

0 · Reply

BeeDecay May. 13 at 12:10 PM

$PSNL With this morning news the last big box that was still unchecked has been checked. For now. All ingredients are now in place for an exponential revenue growth. Again: Chris should speak. He owes us some more detailed guidance and motivating sentences.

0 · Reply

hidjay01 May. 13 at 12:07 PM

$DGXX $RZLV $PSNL

0 · Reply

BeeDecay May. 13 at 11:44 AM

$PSNL $NTRA $GH , With IO reimbursement in place now it might be the case that little Personalis will eat some of the others' lunch quite soon.

0 · Reply

Wax_Bean_futures May. 13 at 11:34 AM

$PSNL OK...........so NOW can we get to $55? 🫡

0 · Reply

Market Cap	605.29M
Revenue (ttm)	69.65M
Net Income (ttm)	-81.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-116.68%
Debt to Equity Ratio	0.00

Volume	1,482,500
Avg Vol	1,800,816
Day's Range	N/A - N/A
Shares Out	104.72M
Stochastic %K	84%
Beta	1.96
Analysts	Strong Sell
Price Target	$11.29